Stock ONC ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Market Closed - Toronto S.E.
Other stock markets
 03:58:07 2024-04-16 pm EDT 		5-day change 1st Jan Change
1.47 CAD +0.68% Intraday chart for Oncolytics Biotech Inc. -5.16% -17.88%
Apr. 11 Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA CI
Apr. 11 Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K
PU
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
AQ
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA
CI
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA
MT
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
MT
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
PR
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference
AQ
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating
MT
Transcript : Oncolytics Biotech Inc., Q4 2023 Earnings Call, Mar 07, 2024
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain
MT
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million
MT
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms
DJ
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
NE
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
CI
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
MT
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
MT
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
AQ
Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
AQ
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. News Oncolytics Biotech Inc.